Marker Therapeutics price target raised to $19 from $11 at Ladenburg

Ladenburg analyst Aydin Huseynov raised the firm’s price target on Marker Therapeutics (MRKR) to $19 from $11 and keeps a Buy rating on the shares. Ladenburg is becoming more confident in seeing additional responses among post-CAR-T diffuse large B-cell lymphoma patients treated with neldaleucel by Q4, and tells investors in a research note that Marker’s management appears focused on gathering a comprehensive dataset with sufficient statistical and clinical significance, which would support advancing to a pivotal Phase 2 trial with a single-arm and single-dose design for neldaleucel. The firm raised its probability of success for neldaleucel to 40% from 25% to 40% in post-CAR-T DLBCL based on the progress observed in this hard-to-treat population.